PL3143011T3 - Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące - Google Patents

Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące

Info

Publication number
PL3143011T3
PL3143011T3 PL15725253T PL15725253T PL3143011T3 PL 3143011 T3 PL3143011 T3 PL 3143011T3 PL 15725253 T PL15725253 T PL 15725253T PL 15725253 T PL15725253 T PL 15725253T PL 3143011 T3 PL3143011 T3 PL 3143011T3
Authority
PL
Poland
Prior art keywords
heterocyclic compounds
imaging agents
deuterated
deuterated heterocyclic
imaging
Prior art date
Application number
PL15725253T
Other languages
English (en)
Inventor
Jan Marik
Joseph P. Lyssikatos
Simon Williams
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3143011T3 publication Critical patent/PL3143011T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
PL15725253T 2014-05-13 2015-05-12 Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące PL3143011T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents
EP15725253.7A EP3143011B1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (1)

Publication Number Publication Date
PL3143011T3 true PL3143011T3 (pl) 2021-07-19

Family

ID=53269446

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15725253T PL3143011T3 (pl) 2014-05-13 2015-05-12 Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące

Country Status (21)

Country Link
US (4) US10076581B2 (pl)
EP (2) EP3901145A1 (pl)
JP (2) JP6529986B2 (pl)
KR (2) KR102530129B1 (pl)
CN (2) CN106459059B (pl)
AU (2) AU2015261008B2 (pl)
CA (1) CA2948721C (pl)
DK (1) DK3143011T3 (pl)
ES (1) ES2867814T3 (pl)
HR (1) HRP20210641T1 (pl)
HU (1) HUE053939T2 (pl)
IL (3) IL280791B2 (pl)
LT (1) LT3143011T (pl)
MX (2) MX2020010847A (pl)
PL (1) PL3143011T3 (pl)
PT (1) PT3143011T (pl)
RS (1) RS61810B1 (pl)
RU (1) RU2696492C2 (pl)
SG (2) SG11201609281UA (pl)
SI (1) SI3143011T1 (pl)
WO (1) WO2015173225A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459059B (zh) 2014-05-13 2019-09-24 豪夫迈·罗氏有限公司 氘化杂环化合物和其作为成像剂的用途
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
EP3487544A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
CA3042260C (en) * 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
US20210041447A1 (en) 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
SG11202112064XA (en) * 2019-05-09 2021-11-29 Hoffmann La Roche Synthesis of labeled imidazo[1,2-a]pyrimidines
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
KR20240049296A (ko) 2021-08-27 2024-04-16 제넨테크, 인크. 타우 병증을 치료하는 방법
WO2023245008A1 (en) 2022-06-13 2023-12-21 Genentech, Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
DD76515A (pl) *
EP1340759A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
PL1999109T3 (pl) * 2006-03-30 2012-05-31 Univ Pennsylvania Pochodne styrylopirydyny i ich zastosowanie do wiązania i obrazowania blaszek amyloidowych
EP2727915B1 (en) * 2007-09-13 2016-04-13 Concert Pharmaceuticals Inc. Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
CA2715390A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8491869B2 (en) 2009-03-23 2013-07-23 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2012065963A2 (en) * 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
KR101609504B1 (ko) * 2012-05-22 2016-04-05 일라이 릴리 앤드 캄파니 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제
KR101770531B1 (ko) * 2013-10-08 2017-08-22 에프. 호프만-라 로슈 아게 타우-펫-리간드로서의 다이아자카르바졸 유도체
CN106459059B (zh) 2014-05-13 2019-09-24 豪夫迈·罗氏有限公司 氘化杂环化合物和其作为成像剂的用途

Also Published As

Publication number Publication date
CA2948721C (en) 2023-03-28
ES2867814T3 (es) 2021-10-20
JP2017515856A (ja) 2017-06-15
US20190201561A1 (en) 2019-07-04
NZ726208A (en) 2023-11-24
EP3143011B1 (en) 2021-03-03
LT3143011T (lt) 2021-05-10
NZ764181A (en) 2023-11-24
AU2019203369A1 (en) 2019-06-06
HRP20210641T1 (hr) 2021-05-28
IL248692A0 (en) 2017-01-31
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
HUE053939T2 (hu) 2021-08-30
RS61810B1 (sr) 2021-06-30
EP3901145A1 (en) 2021-10-27
SI3143011T1 (sl) 2021-08-31
DK3143011T3 (da) 2021-05-03
US20200297875A1 (en) 2020-09-24
US10076581B2 (en) 2018-09-18
IL271631A (en) 2020-02-27
KR102618139B1 (ko) 2023-12-27
MX2016014615A (es) 2017-03-06
KR20170002639A (ko) 2017-01-06
IL280791A (en) 2021-04-29
IL280791B2 (en) 2024-03-01
CN106459059A (zh) 2017-02-22
KR20230035445A (ko) 2023-03-13
AU2019203369B2 (en) 2020-06-04
MX2020010847A (es) 2021-07-16
CN110483522A (zh) 2019-11-22
JP6529986B2 (ja) 2019-06-12
CN106459059B (zh) 2019-09-24
IL271631B (en) 2021-05-31
JP6681498B2 (ja) 2020-04-15
AU2015261008A1 (en) 2016-11-17
US20230218782A1 (en) 2023-07-13
US11504440B2 (en) 2022-11-22
SG11201609281UA (en) 2016-12-29
KR102530129B1 (ko) 2023-05-10
BR112016026443A8 (pt) 2021-07-06
CA2948721A1 (en) 2015-11-19
WO2015173225A1 (en) 2015-11-19
IL248692B (en) 2020-01-30
RU2016147742A3 (pl) 2018-10-08
JP2019147825A (ja) 2019-09-05
EP3143011A1 (en) 2017-03-22
RU2016147742A (ru) 2018-06-18
BR112016026443A2 (pt) 2017-08-15
CN110483522B (zh) 2022-05-03
IL280791B1 (en) 2023-11-01
US20160250358A1 (en) 2016-09-01
US10675367B2 (en) 2020-06-09
PT3143011T (pt) 2021-04-26
AU2015261008B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
IL248692A0 (en) Heterocyclic compounds containing deuterium and their use as imaging agents
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
GB201403093D0 (en) Therapeutic compounds and their use
IL264258B (en) Diazahetero-bicyclic substituted compounds and their use
HK1232137A1 (zh) 治療化合物和組合物
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
ZA201701312B (en) Novel imidazopyridazine compounds and their use
IL247599B (en) Formulation that suppresses the immune system
PL3268356T3 (pl) Związki heterocykliczne i sposoby ich stosowania
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
GB201420506D0 (en) Fresh "N" up
GB201613134D0 (en) Novel compounds and their use
GB201514770D0 (en) Compounds and their use
GB201513318D0 (en) Novel compounds and their use
GB201413411D0 (en) Novel compounds and their use
GB201420795D0 (en) Super sponge
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201411907D0 (en) Targeted imaging agent